vanutide cridificar
Biologicalexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00479557)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
- Beta amyloid A4 proteinVACCINE ANTIGEN
Beta amyloid A4 protein vaccine antigen
Immunotherapeutic vaccine
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108058 ↗
Also known as
- acc-001
- acc-001
- acc-001
- vanutide cridificar
- vanutide cridificar
- vanutide cridificar
- vanutide cridificar
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01227564 | Phase 2 | Feb 1, 2011 | Johnson and Johnson, Pfizer |
| NCT01284387 | Phase 2 | Jan 1, 2011 | Johnson and Johnson, Pfizer |
| NCT01238991 | Phase 2 | Dec 1, 2010 | Johnson and Johnson, Pfizer |
| NCT00955409 | Phase 2 | Nov 1, 2009 | Johnson and Johnson, Pfizer |
| NCT00959192 | Phase 2 | Aug 1, 2009 | Johnson and Johnson, Pfizer |
| NCT00960531 | Phase 2 | Jul 1, 2009 | Johnson and Johnson, Pfizer |
| NCT00752232 | Phase 2 | Dec 1, 2008 | Johnson and Johnson, Pfizer |
| NCT00498602 | Phase 2 | Nov 1, 2007 | Johnson and Johnson, Pfizer |
| NCT00479557 | Phase 2 | May 1, 2007 | Johnson and Johnson, Pfizer |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 9 | 1 | 1 | 2007 |
| Pfizer | For profit | 9 | 8 | 1 | 2007 |
2 organizations
Page 1 / 1